Starton Therapeutics

Starton Therapeutics is a clinical-stage biotechnology platform company that uses proprietary continuous low-dose delivery technology to increase the efficacy and tolerability of approved drugs by maintaining optimal levels of the drug for 24 hrs. a day. Thus, enabling the drugs to ultimately be superior and patients can remain on therapy longer. The company is developing, in parallel, subcutaneous, oral, transdermal, and on-body delivery systems. With multiple delivery methods in development, Starton can expand the number of medicines it is able to deliver continuously, based on patients’ individualized needs and provide multiple avenues for success. Starton’s lead candidate, STAR-LLD, provides a continuous delivery of low-dose lenalidomide (Revlimid®), a drug currently approved for the treatment of adults with multiple myeloma (MM). Despite a good response to lenalidomide, drug-related toxicities remain a challenge that leads to treatment discontinuations. Starton aims to make lenalidomide more effective and tolerable for patients, replacing and expanding the use of Revlimid®. The company is also investigating the use of STAR-LLD in CLL, lymphoma and solid cancers.